{"id":"NCT01281202","sponsor":"Catalyst Pharmaceuticals, Inc.","briefTitle":"Vigabatrin for the Treatment of Cocaine Dependency","officialTitle":"Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2011-01","primaryCompletion":"2012-10","completion":"2012-12","firstPosted":"2011-01-21","resultsPosted":"2016-02-23","lastUpdate":"2016-05-18"},"enrollment":207,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Cocaine Addiction","Cocaine Dependence"],"interventions":[{"type":"DRUG","name":"Vigabatrin","otherNames":["CPP-109","GVG","VGB"]},{"type":"DRUG","name":"Matching Placebo","otherNames":[]}],"arms":[{"label":"CPP-109 Vigabatrin Tablets","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of this 26-28 week study is to demonstrate that the rate of cocaine dependent subjects treated with CPP-109 vigabatrin in addition to counseling, who completely stop use of cocaine in the last 2 weeks of the study's Treatment Phase (Weeks 8 and 9) will be higher than seen in subjects treated with placebo in addition to counseling.","primaryOutcome":{"measure":"Abstinence","timeFrame":"Weeks 8-9","effectByArm":[{"arm":"CPP-109 Vigabatrin Tablets","deltaMin":5,"sd":null},{"arm":"Matching Placebo","deltaMin":9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":1},"locations":{"siteCount":13,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":103},"commonTop":["Headache","Nausea","Fatigue","Back pain","Pain in extremity"]}}